Novo Nordisk cuts cash prices for Wegovy, Ozempic - CNBC Novo Nordisk said it is lowering the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic to $349 per month from $499 per month for existing cash
The Ozempic shortage is over. What now? | College of Public . . . After nearly three years of backorders and pharmacy scrambles, the high-demand weight-loss drugs Ozempic, Wegovy, and Mounjaro are finally back in full supply The FDA recently declared an end to the nationwide shortage of their active ingredients, semaglutide and tirzepatide Martin Binks, chair of the Department of Nutrition and Food Studies at George Mason University and a researcher and